`Perfect anti-cancer drug` CAR-T treatment development to start
Kim Ji Seob | cloud50@ | 2017-11-20 10:14:15
The Korean biotech industry is also jumping into the competition to develop `Chimera antigen receptor-T cell (hereinafter referred to as CAR-T) therapeutic drug` called `dream cancer drug`.
CAR-T is a technique that allows T cells, which are a kind of immune cells existing in the blood, to selectively attack cancer cells. T cells from the patient are extracted by introducing a special gene (CAR), amplifying the T cells containing the gene, and injecting it into the patient`s body.
According to the industry, CAR-T on November 19, a drug developed in the world to date, was approved by the US Food and Drug Administration (FDA) for approval of Kimura, a leukemia drug in Novartis, Switzerland, There are two "Yes Karta". In addition, pharmaceutical companies such as Juno Therapeutics, Atala Biotechnology, France Cellectis, and Takeda Pharmaceutical in Japan are also actively developing drugs for CAR-T.
ViroMed revealed plans to develop CAR-T treatment on the 16th. ViroMed has a CAR gene optimization technology for CAR-T therapeutic development, a vector production technology for maximizing gene delivery efficiency, and an ex vivo technology for gene transfer and cell proliferation. ViroMed plans to develop three CAR-T therapies in December 2015, after transferring the technology of `VM801`, a CAR-T technology developed in-house, to the US Bluebird Bio for about KRW 56.8 billion.
Besides, AFC clone has been developed from the team of Professor Jung Jun-ho of Seoul National University in February as a treatment for blood cancer by introducing more safety technology than existing CAR-T treatment. The team`s technology is known to differentiate itself from existing treatments by significantly reducing the `cytokine release syndrome` (CRS), which is a side effect that causes hypotension or high fever when treating CAR-T.
Meanwhile, Green Cross cell, a subsidiary of Green Cross, is in the process of screening and verifying candidate CAR-T candidates aimed at treating solid tumors. Green Cross cell plans to carry out research with the aim of entering pre-clinical trial next year. LG Chem is reported to be considering the introduction of technology related to the CAR-T treatment system internally, after taking over the head of the life science business of Son Ji-woong in February and making diabetes treatment and immunological anti-cancer drugs the main R & D task.
An industry expert said, "CAR-T treatment is the key to boosting the anti-cancer effect to the maximum extent, and Korea has sufficient technological competitiveness." Commercialization requires collaboration with multinational pharmaceutical companies, but there is a potential to advance into overseas markets." said.
By Kim Ji Seob cloud50@
[ copyright ⓒ The Digitaltimes ]
CAR-T is a technique that allows T cells, which are a kind of immune cells existing in the blood, to selectively attack cancer cells. T cells from the patient are extracted by introducing a special gene (CAR), amplifying the T cells containing the gene, and injecting it into the patient`s body.
According to the industry, CAR-T on November 19, a drug developed in the world to date, was approved by the US Food and Drug Administration (FDA) for approval of Kimura, a leukemia drug in Novartis, Switzerland, There are two "Yes Karta". In addition, pharmaceutical companies such as Juno Therapeutics, Atala Biotechnology, France Cellectis, and Takeda Pharmaceutical in Japan are also actively developing drugs for CAR-T.
ViroMed revealed plans to develop CAR-T treatment on the 16th. ViroMed has a CAR gene optimization technology for CAR-T therapeutic development, a vector production technology for maximizing gene delivery efficiency, and an ex vivo technology for gene transfer and cell proliferation. ViroMed plans to develop three CAR-T therapies in December 2015, after transferring the technology of `VM801`, a CAR-T technology developed in-house, to the US Bluebird Bio for about KRW 56.8 billion.
Besides, AFC clone has been developed from the team of Professor Jung Jun-ho of Seoul National University in February as a treatment for blood cancer by introducing more safety technology than existing CAR-T treatment. The team`s technology is known to differentiate itself from existing treatments by significantly reducing the `cytokine release syndrome` (CRS), which is a side effect that causes hypotension or high fever when treating CAR-T.
Meanwhile, Green Cross cell, a subsidiary of Green Cross, is in the process of screening and verifying candidate CAR-T candidates aimed at treating solid tumors. Green Cross cell plans to carry out research with the aim of entering pre-clinical trial next year. LG Chem is reported to be considering the introduction of technology related to the CAR-T treatment system internally, after taking over the head of the life science business of Son Ji-woong in February and making diabetes treatment and immunological anti-cancer drugs the main R & D task.
An industry expert said, "CAR-T treatment is the key to boosting the anti-cancer effect to the maximum extent, and Korea has sufficient technological competitiveness." Commercialization requires collaboration with multinational pharmaceutical companies, but there is a potential to advance into overseas markets." said.
By Kim Ji Seob cloud50@